Tafalgin is a Russian innovative tetrapeptide pharmaceutical for subcutaneous injection: review of the results of phase I and II clinical trials

Introduction. pain syndrome significantly affects quality of life and daily activities of patients with cancer, especially at terminal stages of the disease. Opioid analgesics are considered the “gold standard” of therapy, but their use is associated with bureaucratic difficulties, as well as risk of a number of adverse events and drug dependency. Tafalgin is a Russian innovative tetrapeptide analgesic for subcutaneous injection. phase I and II clinical trials demonstrated its high effectiveness comparable to morphine and favorable safety profile.

The study objective is to evaluate the safety, tolerability, and pharmacokinetics of tafalgin after subcutaneous injection in healthy volunteers, as well as effectiveness and safety of varying doses in patients with pain syndrome due to malignant tumors.

Materials and methods. Phase I clinical trial included 39 healthy male volunteers. The drug was injected once subcutaneously at doses between 0.05 and 7 mg. plasma samples were obtained in the first 120 hours, and safety profile, tolerability and main pharmacokinetic characteristics of the pharmaceutical were determined. phase II clinical study included 42 patients with severe pain syndrome caused by malignant tumors who previously received morphine. At the 1^st stage (10 days), all patients were randomized in groups receiving tafalgin at doses 2, 3, 4, 5, 6 or 7 mg (dosing frequency was determined individually); at the 2^nd stage the patients were randomized into tafalgin (with dose determined at the 1^st stage) and morphine (with dose determined prior to the clinical trial) groups and received the medications for 7 days. Effectiveness and safety of tafalgin compared to morphine and pharmacokinetic parameters of the studied drug were evaluated.

Results. Tafalgin is characterized by fast absorption after subcutaneous administration (less than 30 minutes) which allows for fast clinical effect and absence of accumulation in the body. use of this pharmaceutical in patients with cancer allowed to maintain appropriate pain management achieved earlier through intramuscular morphine administration in 100 % of cases. Dynamics of mean daily pain intensity and necessity of additional analgesics did not differ between the groups. use of tafalgin did not require an increase in the dose or frequency of administration. Comparison of mean daily individual morphine and tafalgin doses showed that equianalgetic potential of the studied pharmaceutical was 1:3. Safety profile of tafalgin was favorable: adverse events during the trial were mild or moderate and not lifethreatening. use of tafalgin was associated with decreased number of opioid-induced adverse effects and improved quality of sleep in patients who previously received morphine parenterally.

Conclusion. Data obtained during the first in Russia clinical trial of a new selective pharmaceutical tafalgin with tropism to opioid pl-receptors definitively demonstrates its high effectiveness and safety and shows the necessity of further studies in this field.

1. Van den Beuken-van Everdingen M.H.J., de Rijke J.M., Kessels A.G. et al. Prevalence of pain in patients with cancer: a systematic review of the past 40 years. Ann Oncol 2007;18(9):1437-49. DOI: 10.1093/annc/mdm056.

2. Pign T., Fernandez L., Ayasso S., et al. Impact of radiation oncology practice on pain: a cross-sectional survey. Int J Radiat Oncol Biol Phys 2004;60(4):1204-10. DOI: 10.1016/j.ijrobp.2004.04.040.

3. Rietman J.S., Dijkstra P.U., Debreczeni R. et al. Impairments, disabilities and health related quality of life after treatment for breast cancer: a follow-up study 2.7 years after surgery. Disabil Rehabil 2004;26(2):78-84. DOI: 10.1080/09638280310001629642.

4. Taylor K.O. Morbidity associated with axillary surgery for breast cancer. ANZ J Surg 2004;74(5):314-7. DOI: 10.1111/j.1445-1433.2004.02992.x.

5. Bradley N., Davis L., Chow E. Symptom distress in patients attending an outpatient palliative radiotherapy clinic. J Pain Symptom Manage 2005;30(2):123—31. DOI: 10.1016/j.jpainsymman.2005.02.015.

6. Di Maio M., Gridelli C., Gallo C. et al. Prevalence and management of pain in Italian patients with advanced nonsmall-cell lung cancer. Br J Cancer 2004;90(12):2288-96. DOI: 10.1038/sj.bjc.6601810.

7. Hwang S.S., Chang V.T., Cogswell J. et al. Study of unmet needs in symptomatic veterans with advanced cancer: incidence, independent predictors and unmet needs outcome model. J Pain Symptom Manage 2004;28(5):421-32. DOI: 10.1016/j.jpainsymman.2004.02.023.

8. Van den Beuken-van Everdingen M.H.J., Hochstenbach L.M.J., Joosten E.A.J. et al. Update on prevalence of pain in patients with cancer: systematic review and metaanalysis. J Pain Symptom Manage 2016;51(6):1070-90. DOI: 10.1016/j.jpainsymman.2015.12.340.

9. Kroenke K., Theobald D., Wu J. et al. The association of depression and pain with health-related quality of life, disability, and health care use in cancer patients. J Pain Symptom Manage 2010;40(3):327-41. DOI: 10.1016/j.jpainsymman.2009.12.023.

10. Deng D., Fu L., Zhao Y.X. et al. The relationship between cancer pain and quality of life in patients newly admitted to Wuhan Hospice Center of China. Am J Hosp Palliat Care 2012;29(1):53-9. DOI: 10.1177/1049909111418636.

11. Porter L.S., Keefe F.J. Psychosocial issues in cancer pain. Curr Pain Headache Rep 2011;15(4):263-70. DOI: 10.1007/s11916-011-0190-6.

12. Rief W., Bardwell W.A., Dimsdale J.E. et al. Long-term course of pain in breast cancer survivors: a 4-year longitudinal study. Breast Cancer Res Treat 2011;130(2):579-86. DOI: 10.1007/s10549-011-1614-z.

13. Breivik H., Cherny N., Collett B. et al. Cancer-related pain: a pan-European survey of prevalence, treatment, and patient attitudes. Ann Oncol 2009;20(8): 1420-33. DOI: 10.1093/annc/mdp001.

14. He Q.-H., Liu Q.-L., Li Z. et al, Impact of epidural analgesia on quality of life and pain in advanced cancer patients. Pain Manag Nurs 2015;16(3):307-13. DOI: 10.1016/j.pmn.2014.08.003.

15. Ovayolu N., Ovayolu O., Serije S. et al. Pain and quality of life in Turkish cancer patients. Nurs Health Sci 2013;15(4):437-43. DOI: 10.1111/nhs.12047.

16. Oliveira K.G., von Zeidler S.V., Podesta J. et al. Influence of pain severity on the quality of life in patients with head and neck cancer before antineoplastic therapy. BMC Cancer 2014;14:39. DOI: 10.1186/1471-2407-14-39.

17. Bona L.G., Geleta D., Dulla D. et al. Ecomic burden of cancer on cancer patients treated at Hawassa University Comprehensive Specialized Hospital. Cancer Control. 2021;28:107327482110 09252. DOI: 10.1177/10732748211009252.

18. Chronic pain syndrome (CBS) in adult patients in need of palliative care. Clinical recommendations. 2016. (In Russ.). Available at: https://b67c110e-c342-4f50-9588-194d66f0d842.filesusr.com/ugd/b488e5_3a5e5299af1645fda81a3cf6d5f2cdd6.pdf.

19. Cleary J.F. The pharmacologic management of cancer pain. J Palliat Med 2007;10(6):1369-94. DOI: 10.1089/jpm.2007.9842.

20. Anekar A.A., Cascella M. WHO Analgesic Ladder, in StatPearls, Treasure Island (FL): StatPearls Publishing, 2022. Available at: http://www.ncbi.nlm.nih.gov/books/NBK554435/

21. WHO, WHO guidelines for the pharmacological and radiotherapeutic management of cancer pain in adults and adolescents. 2018. Available at: https://www.who.int/publications/i/item/9789241550390.

22. Bennett M., Paice J.A., Wallace M. Pain and opioids in cancer care: benefits, risks, and alternatives. Am Soc Clin Oncol Educ Book 2017;37:705-13. DOI: 10.1200/EDBK_180469.

23. Kosten T.R., George T.P. The neurobiology of opioid dependence: implications for treatment. Sci Pract Perspect 2002; 1(1):13-20. DOI: 10.1151/spp021113.

24. Nevzorova D.V., Abuzarova G.R., Polevichenko E.V., Shershakova L.V. Availability of opioid analgesics in the treatment of chronic pain in Russia. The current state of the problem. Review. Pallium: Palliativnaya i hos-pisnaya pomoshch' = Pallium Palliative and Hospice Care 2020;2(7). (In Russ.). Available at: https://www.elibrary.ru/item.asp?id=45812916&.

25. Mercadante S. Options for treating pain in cancer patients with dysphagia. Drugs 2017;77(6):629-35. DOI: 10.1007/s40265-017-0710-8.

26. Storey P., Hill H.H., St. Louis R.H., Tarver E.E. Subcutaneous infusions for control of cancer symptoms. J Pain Symptom Manage 1990;5(1):33-41. DOI: 10.1016/S0885-3924(05)80007-7.

27. Bhattacharyya G.S. Oral systemic therapy: not all “win-win”. Indian J Med Paediatr Oncol 2010;31(1):1-3. DOI: 10.4103/0971-5851.68844.

28. Letizia M., Shenk J., Jones T.D. Intermittent subcutaneous injections of pain medication: effectiveness, manageability, and satisfaction. Am J Hosp Palliat Care 1999;16(4):585-92. DOI: 10.1177/104990919901600407.

29. Furst P., Lundstrom S., Klepstad P., Strang P. Continuous subcutaneous infusion for pain control in dying patients: experiences from a tertiary palliative care center. BMC Palliat Care 2020;19(1):172. DOI: 10.1186/s12904-020-00681-3.

30. Crane R.A. Intermittent subcutaneous infusion of opioids in hospice home care: an effective, ecomical, manageable option. Am J Hosp Palliat Care 1994;11(1):8-12. DOI: 10.1177/104990919401100103.

31. Harned M., Sloan P. Safety concerns with long-term opioid use. Expert Opin Drug Saf 2016;15(7):955-62. DOI: 10.1080/14740338.2016.1177509.

32. Benyamin R., Trescot A.M., Datta S. et al. Opioid complications and side effects. Pain Physician 2008;11(2):105-20.

33. Daniell H.W. Hypogonadism in men consuming sustained-action oral opioids. J Pain 2002;3(5):377-84. DOI: 10.1054/jpai.2002.126790.

34. Abs R., Verhelst J., Maeyaert J. et al. Endocrine consequences of long-term intrathecal administration of opioids. J Clin Endocril Metab 2000;85(6):2215-22. DOI: 10.1210/jcem.85.6.6615.

35. Daniell H.W. Opioid endocripathy in women consuming prescribed sustained-action opioids for control of nmalignant pain. J Pain 2008;9(1):28—36. DOI: 10.1016/j.jpain.2007.08.005.

36. Walker J.M., Farney R.J., Rhondeau S.M. et al. Chronic opioid use is a risk factor for the development of central sleep apnea and ataxic breathing. J Clin Sleep Med 2007;3(5):455-61.

37. Strassels S.A. Cognitive effects of opioids. Curr Pain Headache Rep 2008;12(1):32-6. DOI: 10.1007/s11916-008-0007-4.

38. Boom M., Niesters M., Sarton E. et al. Non-analgesic effects of opioids: opioid-induced respiratory depression. Curr Pharm Des 2012;18(37):5994-6004. DOI: 10.2174/138161212803582469.

39. Kata V., Vitch M.B., Jones M.R. et al. Opioid addiction, diversion, and abuse in chronic and cancer pain. Curr Opin Support Palliat Care 2018;12(2):124-30. DOI: 10.1097/SPC.0000000000000333.

40. Bruera E., Paice J.A. Cancer pain management: safe and effective use of opioids. Am Soc Clin Oncol Educ Book 2015:e593-9. DOI: 10.14694/EdBook_AM.2015.35.e593.

41. Mercadante S., Portey R.K. Breakthrough cancer pain: twenty-five years of study. Pain 2016;157(12):2657-63. DOI: 10.1097/j.pain.0000000000000721.

42. Portey R.K., Payne D., Jacobsen P. Breakthrough pain: characteristics and impact in patients with cancer pain. Pain 1999;81(1-2):129-34. DOI: 10.1016/s0304-3959(99)00006-8.

43. Bruera E., Fainsinger R., MacEachern T., Hanson J. The use of methylphenidate in patients with incident cancer pain receiving regular opiates. A preliminary report. Pain 1992;50(1):75-7. DOI: 10.1016/0304-3959(92)90114-Q.

44. Fine P.G., Busch M.A. Characterization of breakthrough pain by hospice patients and their caregivers. J Pain Symptom Manage 1998;16(3):179-83. DOI: 10.1016/S0885-3924(98)00045-1.

45. Gomez-Batiste X., Madrid F., Moreno F. et al. Breakthrough cancer pain: prevalence and characteristics in patients in Catalonia, Spain. J Pain Symptom Manage 2002;24(1):45-52. DOI: 10.1016/s0885-3924(02)00421-9.

46. Davies A., Zeppetella G., Andersen S. et al. Multicentre European study of breakthrough cancer pain: pain characteristics and patient perceptions of current and potential management strategies. Eur J Pain 2011;5(7):756-63. DOI: 10.1016/j.ejpain.2010.12.004.

47. Taylor D.R., Webster L.R., Chun S.Y. et al. Impact of breakthrough pain on quality of life in patients with chronic, noncancer pain: patient perceptions and effect of treatment with oral transmucosal fentanyl citrate (OTFC, ACTIQ). Pain Med 2007;8(3):281-8. DOI: 10.1111/j.1526-4637.2007.00298.x.

48. Abuzarova G.R., Lapina S.E., Sarmanaeva R.R. “Breakthrough pain” is a new term, not a new problem. Rossijskij zhurnal boli = Russian Journal of Pain 2017;54(3-4):8-17. (In Russ.).

49. Pitt J.J. Principles and applications of liquid chromatography-mass spectrometry in clinical biochemistry. Clin Biochem Rev 2009;30(1):19-34.

50. Ogu C.C., Maxa J.L. Drug interactions due to cytochrome P450. Proc Bayl Univ Med Cent 2000;13(4):421-3. DOI: 10.1080/08998280.2000.11927719.

51. Smith H.S. Opioid metabolism. Mayo Clin Proc 2009;84(7):613-24.

52. Mercadante S., Intravaia G., Villari P. et al. Intraveus morphine for breakthrough (episodic-) pain in an acute palliative care unit: a confirmatory study. J Pain Symptom Manage 2008;35(3):307-13. DOI: 10.1016/j.jpainsymman.2007.04.018.

53. Mercadante S., Villari P., Ferrera P. et al. Safety and effectiveness of intraveus morphine for episodic (breakthrough) pain using a fixed ratio with the oral daily morphine dose. J Pain Symptom Manage 2004;27(4):352-9. DOI: 10.1016/j.jpainsymman.2003.09.006.

54. Jakobsen G., Engstrom M., Fayers P. et al. Sleep quality with WHO Step III opioid use for cancer pain. BMJ Support Palliat Care 2019;9(3):307-15. DOI: 10.1136/bmjspcare-2017-001399.

55. Kamboj S.K., Tookman A., Jones L., Curran V.H. The effects of immediate-release morphine on cognitive functioning in patients receiving chronic opioid therapy in palliative care. Pain 2005;117(3):388-95. DOI: 10.1016/j.pain.2005.06.022.

56. Okamoto Y., Tsuneto S., Tsugane M. et al. A retrospective chart review of opioid-induced nausea and somlence on commencement for cancer pain treatment. J Opioid Manag 2010;6(6):431-4. DOI: 10.5055/jom.2010.0041.

57. Sugawara H., Uchida M., Suzuki S. et al. Analyses of respiratory depression associated with opioids in cancer patients based on the Japanese adverse drug event report database. Biol Pharm Bull 2019;42(7):1185-91. DOI: 10.1248/bpb.b19-00105.